Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Peter Reichardt(Helios Hospital Berlin-Buch), T. Deist(Institut für Bodenkultur und Pflanzenbau), Bernhard Gebauer(Charité - Universitätsmedizin Berlin), Kirstin Breithaupt(Charité - Universitätsmedizin Berlin), Guido Schumacher(Charité - Universitätsmedizin Berlin), Axel Hinke, Dmitry Bichev(Charité - Universitätsmedizin Berlin), Albrecht Kretzschmar(Roche (Switzerland)), Yasemin Doğan(Charité - Universitätsmedizin Berlin)
European Journal of Cancer
July 13, 2011
10.1016/j.ejca.2011.06.002
Cited by 615

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|751